Table 2.

Means [95% confidence limits] for laboratory and domiciliary diary card data for pooled placebo and each randomized treatment.

	Pooled placebo	Montelukast First dose	Last dose	Formoterol First dose	Last dose
AMP PC20 (mg ml−1)	36.3 [27.5–49.0]	79.4*[58.9–104.7]	74.6*[55.9–99.5]	91.2*[56.2–151.4]	45.7 [28.2–75.9]
NO (p.p.b)	13.3 [9.7–16.8]	12.9 [9.3–16.4]	8.83 [5.3–12.4]	13.6 [11.3–15.8]	11.3 [9.0–13.5]
EOS (× 106 l−1)	333 [294–372]	312 [271–353]	261*[222–300]	327 [263–390]	353 [289–416]
FEV1 (l)	2.50 [2.35–2.65]	2.51 [2.38–2.63]	2.47 [2.35–2.60]	2.67 [2.52–2.82]	2.43 [2.28–2.58]
FEF25-75 (l s−1)	1.85 [1.71–2.00]	1.92 [1.78–2.07]	1.91 [1.76–2.05]	2.23*[2.05–2.40]	1.95 [1.78–2.12]
PEF [lab] (l min−1)	395 [380–415]	400 [380–420]	410 [390–425]	430*[415–450]	410 [390–42]

Means [95% confidence intervals] adenosine monophosphate PC₂₀ (AMP PC₂₀), exhaled nitric oxide (NO), blood eosinophil count (EOS), forced expiratory volume in 1 second (FEV₁), forced mid expiratory flow (FEF_25-75)), laboratory peak expiratory flow (PEFlab), domiciliary morning/evening peak expiratory flow (PEFam/pm), daytime/night-time symptom score (SYMam/pm) and daytime/night-time rescue bronchodilator requirement (RESam/pm).

^*Denotes a significant difference between pooled placebo and randomized treatments.